<DOC>
	<DOCNO>NCT01902459</DOCNO>
	<brief_summary>The objective study evaluate clinical utility EVARREST™ Fibrin Sealant Patch ( Fibrin Pad ) adjunct hemostasis soft tissue bleed intra-abdominal ( stomach area ) , retroperitoneal ( hip stomach area ) , pelvic ( hip area ) non-cardiac thoracic ( chest area ) surgery .</brief_summary>
	<brief_title>EVARREST™ Fibrin Sealant Patch Post-Market Study</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Subjects ≥18 year age , require elective urgent , open intraabdominal , retroperitoneal , pelvic noncardiac thoracic surgical procedure ; Subjects legally authorize representative must willing participate study provide write informed consent . Presence appropriate Target Bleeding Site identify intraoperatively surgeon ; Subjects know intolerance blood product one component EVARREST™ unwilling receive blood product ; Female subject pregnant nursing . TBS large defect artery vein injure vascular wall require repair maintenance vessel patency would persistent exposure EVARREST™ blood flow and/or pressure absorption product ; TBS major arterial bleed require suture mechanical ligation ; TBS within contaminate infected area body ; Bleeding site , around , proximity foramen bone , area bony confine ; Subjects intraoperative finding identify surgeon may preclude conduct study procedure ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hemostasis</keyword>
</DOC>